2018’s Top Biopharma Deal-makers
2018’s Top Biopharma Deal-makers
$131.00
How did biopharma shape up for 2018 in terms of mergers, acquisitions, and other business deals? Explore what transpired during last year for M&A in biopharma, when tax cuts were expected to spur major activity. In Vivo brings you a vital look back at the events of 2018.
Author: Amanda Micklus
Publisher: InVivo
- Description
Which major deals marked 2018 M&A, a year during which the industry had high expectations for deal activity, given the anticipation of favorable tax breaks in the US? Explore what deals and companies showed the most activity, take a look at the year’s biggest deals and areas of interest, and understand the trends that 2018’s M&A deals may indicate for the future with this informative look at the market from In Vivo. Covered is a look at in-licensing, acquisitions, top deals by therapeutic area, and IPO and VP investment in various therapeutic areas.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
The Gene Therapies Are Coming – And So Are New Ways To Pay For Them 
Sign up to the